文献速递肿瘤 PET/CT核素与放射性配体治疗

CD8靶向PET成像在癌症患者肿瘤浸润T细胞中的应用:89Zr-Df-IAB22M2C的I期首次人体研究

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.
PubMed 文献 · J Nucl Med · 2021-08-19

该I期首次人体研究使用抗CD8放射性标记微抗体89Zr-Df-IAB22M2C,对15例转移性实体瘤患者进行PET成像,以检测全身和肿瘤CD8+白细胞分布。研究显示该显像剂安全,肿瘤摄取在10/15例患者中可见,包括7/8例免疫治疗患者,且免疫治疗后CD8 PET/CT摄取增加与疗效相关。

要点

  • 89Zr-Df-IAB22M2C CD8 PET成像安全,仅1例出现短暂抗药抗体升高。
  • 肿瘤摄取见于10/15例患者,免疫治疗患者中7/8例可见。
  • 免疫治疗后CD8 PET/CT肿瘤摄取增加与疗效相关。

核心结论

  • CD8 PET成像使用89Zr-Df-IAB22M2C安全,可可视化肿瘤和参考组织中CD8+白细胞的全身生物分布,并可能预测免疫治疗的早期反应。

研究设计与样本

  • I期首次人体PET成像研究,采用两阶段设计包括剂量递增和剂量扩展阶段,纳入15例转移性实体瘤患者。
  • 患者接受111 MBq 89Zr-Df-IAB22M2C,随后在5-7天内进行系列PET扫描。

主要发现

  • 15例转移性黑色素瘤、非小细胞肺癌和肝细胞癌受试者入组,除1例受试者出现短暂抗药抗体增加外,无药物相关不良事件或异常实验室结果。
  • 89Zr-Df-IAB22M2C在肿瘤和CD8丰富组织(如脾、骨髓、淋巴结)中积聚,注射后24-48小时达最大摄取,CD8贫乏组织(如肌肉和肺)背景活性低。
  • 10/15例受试者肿瘤中观察到放射性示踪剂摄取,包括7/8例接受免疫治疗者、1/2例接受靶向治疗者和2/5例未治疗者。
  • 3例接受免疫治疗的晚期黑色素瘤或肝细胞癌患者,治疗后CD8 PET/CT显示肿瘤病灶89Zr-Df-IAB22M2C摄取增加,与疗效相关。

临床怎么用

  • CD8 PET成像可用于无创评估肿瘤CD8+白细胞分布,可能辅助预测免疫治疗早期反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response to cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies or immunotherapy combinations. This study was designed to optimize conditions for performing CD8 PET imaging with 89Zr-Df-IAB22M2C and determine whether CD8 PET imaging could provide a safe and effective noninvasive method of visualizing the whole-body biodistribution of CD8+ leukocytes. Methods: We conducted a phase 1 first-in-humans PET imaging study using an anti-CD8 radiolabeled minibody, 89Zr-Df-IAB22M2C, to detect whole-body and tumor CD8+ leukocyte distribution in patients with metastatic solid tumors. Patients received 111 MBq of 89Zr-Df-IAB22M2C followed by serial PET scanning over 5-7 d. A 2-stage design included a dose-escalation phase and a dose-expansion phase. Biodistribution, radiation dosimetry, and semiquantitative evaluation of 89Zr-Df-IAB22M2C uptake were performed in all patients. Results: Fifteen subjects with metastatic melanoma, non-small cell lung cancer, and hepatocellular carcinoma were enrolled. No drug-related adverse events or abnormal laboratory results were noted except for a transient increase in antidrug antibodies in 1 subject. 89Zr-Df-IAB22M2C accumulated in tumors and CD8-rich tissues (e.g., spleen, bone marrow, nodes), with maximum uptake at 24-48 h after injection and low background activity in CD8-poor tissues (e.g., muscle and lung). Radiotracer uptake in tumors was noted in 10 of 15 subjects, including 7 of 8 subjects on immunotherapy, 1 of 2 subjects on targeted therapy, and 2 of 5 treatment-naïve subjects. In 3 patients with advanced melanoma or hepatocellular carcinoma on immunotherapy, posttreatment CD8 PET/CT scans demonstrated increased 89Zr-Df-IAB22M2C uptake in tumor lesions, which correlated with response. Conclusion: CD8 PET imaging with 89Zr-Df-IAB22M2C is safe and has the potential to visualize the whole-body biodistribution of CD8+ leukocytes in tumors and reference tissues, and may predict early response to immunotherapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Farwell MD, Gamache RF, Babazada H, et al. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. J Nucl Med. 2021. PMID: 34413145. doi:10.2967/jnumed.121.262485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。